Dual chromophore PACK-CXL treatment using riboflavin/UV-A and rose bengal/green light may offer an effective solution for refractory Acanthamoeba keratitis.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
In a recent feature, Ocular Surgery News (OSN) provided an in-depth overview of the latest advancements in epi-on crosslinking, as presented by Prof. Farhad Hafezi of the ELZA Institute at the Winter ESCRS meeting in Frankfurt, Germany.
Epi-On Cross-Linking goes office-based! ELZA’s innovation eliminates bulky equipment, offering streamlined keratoconus care, tells Farhad Hafezi to Ocular Surgery News.
Central Asian University (CAU) recently hosted a highly anticipated guest lecture on “Enterprising Ophthalmology,” featuring ELZA’s CEO and CMO, Nikki and Farhad Hafezi.
Exploring comprehensive keratoconus treatment, from cross-linking to surgery, in the highly respected scientific journal Nature Reviews.
Corneal Physician reports on ELZA’s exploration of slit-lamp CXL as a promising, accessible treatment for infectious keratitis.
Prof. Farhad Hafezi from the ELZA Institute provided an insightful update on the Second Global Consensus on Keratoconus during an interview with EyeTube.
In a recently published case report in American Journal of Ophthalmology Case Reports, our team, in collaboration with Brazilian colleagues, describes an unusual case of a “CTK-like syndrome” following sequential intracorneal ring segment (ICRS) implantation and corneal cross-linking (CXL) in a young patient with progressive keratoconus.
Prof. Hafezi presents Femto-CAIRS and high fluence cross-linking, highlighting its advantages for keratoconus treatment and improving visual outcomes
